

IMIDAZOLINE RECEPTOR ANTISERA-
SELECTED PROTEIN: A UNIQUE
MODULATOR OF NEURONAL
DIFFERENTIATION

Francis Christian Dehle, Bachelor of Science (Hons)

Discipline of Pharmacology, School of Medical Sciences

The University of Adelaide

(Faculty of Health Science)

July 2008

A thesis submitted for the degree of Doctor of Philosophy

Table of Contents

Abstract	ix
Declaration	xi
Acknowledgements	xii
Published Communications	xiii
Abbreviations	xiv
1 Introduction	1
1.1 The imidazoline I ₁ receptor	2
1.1.1 Discovery	2
1.1.2 Radioligand binding studies	2
1.1.3 I ₁ -R compounds.....	3
1.1.4 I ₁ Receptors and blood pressure	4
1.1.5 Endogenous ligands	5
1.1.6 I ₁ -Rs and signal transduction	6
1.1.6.1 PC12 cells	6
1.1.6.2 Early studies	6
1.1.6.3 Diacylglycerol production/ phosphatidylcholine-specific phospholipase C activation	7

1.1.6.4	Arachidonic acid production/ protein kinase C activation/MAP kinase activation8	
1.2	IRAS.....	9
1.2.1	Discovery	9
1.2.2	IRAS structure.....	10
1.2.3	Location	12
1.2.4	IRAS as an I ₁ -R.....	13
1.2.5	Cell migration and Rac signalling.....	14
1.2.6	Cell survival	16
1.2.7	Interaction with other receptors	16
1.3	IRAS and neuronal development	18
1.3.1	Growth cones and neuronal cell growth	18
1.3.2	NGF/TrkA.....	19
1.3.2.1	PLC- γ 1 signalling.....	20
1.3.2.2	MAP kinase signalling	20
1.3.2.3	PI3-kinase signalling.....	22
1.3.2.4	Retrograde TrkA signalling.....	23
1.3.3	Integrins	24
1.3.3.1	Structure	24
1.3.3.2	Mediation of cell morphology.....	24
1.3.3.3	Signal transduction.....	25
1.3.4	Lysophospholipid receptors	26
1.3.4.1	LPA	26
1.3.4.2	S1P	27
1.3.4.3	Interaction with clonidine	28

1.4	Aims and objectives	29
2	Methods and materials.....	39
2.1	PC12 cell culture	39
2.2	F-actin staining.....	39
2.2.1	Preparation of coverslips.....	39
2.2.2	Preparation of cells.....	40
2.3	Western blotting	41
2.3.1	Preparation of cell lysates	41
2.3.2	Protein concentration assay	41
2.3.3	Western blotting	42
2.3.4	Immunodetection	43
2.3.5	Membrane stripping and re-probing.....	44
2.4	Drugs and reagents.....	44
3	Chapter 3: Effect of IRAS on growth cone formation	46
3.1	Introduction.....	46
3.2	Methods.....	49
3.2.1	F-actin staining.....	49
3.2.2	Growth cone assay	49
3.2.3	Statistics	50
3.3	Results.....	51
3.3.1	IRAS modulates F-actin organization in PC12 cells.....	51
3.3.2	IRAS increases growth cone development	51
3.3.3	Effect of rilmenidine and AGN192403 on growth cone development in PC12 cells	52

3.4	Discussion	58
3.4.1	Effect of integrin on growth cone formation.....	59
3.4.2	Effect of I ₁ -R ligands	62
3.5	Conclusion	64
4	Chapter 4: Effect of IRAS on NGF-induced neurite outgrowth and ERK1/2 activation	65
4.1	Introduction.....	65
4.2	Methods.....	68
4.2.1	Neurite outgrowth	68
4.2.2	ERK1/2 activation.....	68
4.2.3	Statistics	69
4.3	Results.....	70
4.3.1	The effect of IRAS on NGF-induced neurite outgrowth	70
4.3.2	The effect of IRAS on NGF-induced ERK1/2 activation	71
4.3.3	The effect of IRAS on EGF-induced ERK1/2 activation.....	71
4.4	Discussion	80
4.4.1	Neurite outgrowth	80
4.4.2	Effect of IRAS on NGF signalling.....	82
4.5	Conclusion	86
5	Chapter 5: I₁-R and PI3-kinase signalling in IRAS modulation of NGF-induced ERK1/2 activation	87
5.1	Introduction.....	87
5.2	Methods.....	90
5.2.1	ERK1/2 activation.....	90

5.2.2	Src activation.....	90
5.2.3	Statistics	90
5.3	Results.....	91
5.3.1	The effect of AGN192403, D609 and wortmannin on NGF-induced ERK1/2 activation.....	91
5.3.2	The effect of IRAS on NGF-induced Src activation.....	91
5.4	Discussion	97
5.5	Conclusion	102
6	Chapter 6: Role of IRAS in NGF and LP receptor agonist interaction	104
6.1	Introduction.....	104
6.2	Methods.....	107
6.2.1	ERK1/2 activation.....	107
6.2.2	Neurite outgrowth	107
6.2.3	Statistics	108
6.3	Results.....	109
6.3.1	The effect of LPA and SEW2871 on NGF-induced ERK1/2 activation 109	
6.3.2	The effect of LPA and SEW2871 pre-treatment on NGF-induced ERK1/2 activation and neurite outgrowth.....	110
6.4	Discussion	118
6.4.1	Effect of IRAS on LP receptor agonist-induced ERK1/2 activation	118
6.4.2	Effect of LP receptor agonist pre-treatment on ERK1/2 activation and neurite outgrowth	121
6.5	Conclusion	123

7	Chapter 7: General discussion.....	124
7.1	Summary	124
7.2	Is IRAS a receptor or trafficking protein?.....	126
7.3	Is IRAS an Imidazoline binding protein?.....	127
7.4	IRAS in neuronal cell signalling.....	130
7.4.1	TrkA signalling	130
7.4.2	LP receptor signalling	132
7.4.3	Potential clinical implications.....	133
7.4.4	Future directions	136
7.5	Conclusion	137
	Appendix I	140
	References.....	145
	List of Tables	
	Table 1.1. Affinities of various agonist drugs for I ₁ -Rs and α_{2a} -adrenoceptors.	31
	Table 1.2. Affinities of various antagonist drugs for I ₁ -Rs and α_{2a} -adrenoceptors.	32
	Table 1.2. Lysophospholipid receptor G-protein coupling and signalling.....	38
	List of Figures	
	Figure 1.1. I ₁ -R signal transduction.	33
	Figure 1.2. Schematic diagram of IRAS structure showing relative positions of important structural domains.	33

Figure 1.3. Inhibition of [¹²⁵ I]p-iodoclonidine binding in IRAS-transfected CHO cells (graph from Piletz <i>et al.</i> , 2000).	34
Figure 1.4. Effect of Nischarin on actin organisation in REF cells.	34
Figure 1.5. Downstream pathways from RhoA, Rac1 and Cdc42 that control stress fibre and growth cone formation.	35
Figure 1.6. Growth cone dynamics and morphology.	36
Figure 1.7 NGF signalling pathways	36
Figure 1.8 NGF signalling from endosomes.	37
Figure 1.9. Integrin signalling.	37
Figure 3.1. Effect of IRAS on F-actin distribution.	54
Figure 3.2. Effect of IRAS on growth cone development.	55
Figure 3.3. Effect of rilmenidine and AGN192403 on growth cone development.	56
Figure 3.4. Effect of rilmenidine and AGN192403 on percentage of cells with growth cones and growth cone length.	57
Figure 4.1. Effect of IRAS on NGF-induced neurite outgrowth in full-serum conditions.	73
Figure 4.2. Percent of vector- and IRAS-transfected cells expressing neurites in full- serum conditions.	74
Figure 4.3. Effect of IRAS on NGF-induced neurite outgrowth in serum-starved conditions.	75
Figure 4.4. Percent of vector- and IRAS-transfected cells expressing neurites in serum- starved conditions.	76
Figure 4.5. Effect of IRAS on NGF-induced ERK1/2 activation under full-serum conditions.	77

Figure 4.6. Effect of IRAS on NGF-induced ERK1/2 activation under serum-starved conditions.	78
Figure 4.7. Effect of IRAS on EGF-induced ERK1/2 activation under full-serum conditions.	79
Figure 5.1. Effect of AGN192403 on NGF-induced ERK1/2 activation.....	93
Figure 5.2. Effect of D609 on NGF-induced ERK1/2 activation.	94
Figure 5.3. Effect of wortmannin on NGF-induced ERK1/2 activation.....	95
Figure 5.4. Effect of IRAS on Src activation.	96
Figure 6.1. Effect of LPA and SEW2871 on NGF-induced ERK1/2 activation.....	112
Figure 6.2. Effect of LPA, AGN192403 and efaroxan on NGF-induced ERK1/2 activation.	113
Figure 6.3. Effect of LPA and SEW2871 pre-treatment on NGF-induced ERK1/2 activation.	114
Figure 6.4. Effect of LPA and SEW2871 pre-treatment on NGF-induced neurite outgrowth in vector-transfected cells grown in serum-starved conditions.	115
Figure 6.5. Effect of LPA and SEW2871 pre-treatment on NGF-induced neurite outgrowth in IRAS-transfected cells grown in serum-starved conditions.	116
Figure 6.6. Effect of LPA and SEW2871 on percent of NGF-treated vector- and IRAS-transfected cells expressing neurites in serum-starved conditions.....	117
Figure 7.1. Model of IRAS signalling through TrkA trafficking.....	138
Figure 7.2. Model of IRAS signalling through LP receptor trafficking.....	139
Figure A-1. Western blots and Immunoprecipitations using IRAS and Trk antibodies.	143
Figure A-2. Immunocytochemistry using IRAS and Trk antibodies	144

Abstract

The imidazoline I₁ receptor (I₁-R) is a novel receptor found primarily in the brain and nervous tissue where it modulates neurotransmission. It is named for its high affinity for compounds with an imidazoline structure such as the anti-hypertensive drugs, clonidine and moxonidine.

The imidazoline receptor antisera-selected protein (IRAS) is the putative clone of the I₁-R. IRAS has a unique structure, which does not resemble any other receptor protein. IRAS is present throughout the body with highest levels in the brain. There is a growing body of research examining the physiological roles of IRAS as an I₁-R, in cell survival, migration and protein trafficking. However, there is little research into its neuronal functions.

IRAS interacts with other membrane receptors: the mouse homologue of IRAS reorganises the actin cytoskeleton through interaction with the $\alpha 5\beta 1$ fibronectin receptor. IRAS also binds insulin receptor substrate 4 and enhances insulin-induced extracellular signal-regulated kinase1/2 (ERK1/2) activation. Actin reorganisation and ERK1/2 activation are important for the development of neurites during neuronal differentiation. Therefore, the work described in this thesis aimed to investigate the effects of IRAS on neuronal differentiation. Studies reported in this thesis also aimed to investigate whether IRAS affected ERK1/2 signalling of other receptors involved in neuronal differentiation such as the NGF receptor, TrkA, and lysophospholipid receptors.

The above aims were carried out in neuronal model PC12 cells transfected with either IRAS or a vector plasmid. Fluorescence microscopy and Western blotting techniques were used to examine the effect of IRAS on cell morphology and ERK1/2 signalling.

The work described in this thesis found that IRAS reorganises the actin cytoskeleton and enhances growth cone development in PC12 cells. This study also shows that IRAS differentially enhances or inhibits NGF-induced PC12 cell differentiation depending on the presence or absence of serum in the media. In full-serum conditions, IRAS enhanced neurite outgrowth and this was accompanied by an increase in ERK1/2 activation. In serum-starved cells, IRAS inhibited neurite outgrowth with similar levels of ERK1/2 activation observed in vector- and IRAS-transfected cells. Finally, studies presented in this thesis found that IRAS enhances lysophosphatidic acid-induced ERK1/2 activation and that IRAS interacting with lysophospholipid receptor agonists present in serum is a potential mechanism by which it enhances NGF-induced ERK1/2 activation in full-serum conditions.

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying.

Signed:..... Date:.....

Acknowledgements

I would like to thank a number of people and organisations for their help towards the completion of this thesis:

Firstly, I would like to thank my supervisor, Dr Ian Musgrave, for his great support, guidance and endless enthusiasm during the course of this project.

I would also like to thank my associate supervisor, Assoc. Prof. Phil Burcham, for his valuable feedback on the thesis.

I am also grateful to Rod Irvine, Meredith Wallwork, Yvette DeGraaf and John Piletz for various forms of assistance along the way. I would especially like to thank Prof. John Piletz for providing the PC12 cells used in this study and the IRAS antibody.

I would like to acknowledge The University of Adelaide and the Discipline of Pharmacology for providing the opportunity and funding for this project.

I would also like to acknowledge past and present members of the Musgrave and Burcham research groups for their encouragement and assistance. In particular, I would like to thank Kosta Farmakis for his friendly advice and good humour.

Finally, I would like to thank my friends and family for their support and encouragement. I would especially like to thank my mum, Lyn, for her invaluable advice and continual support throughout the project.

Published Communications

- Dehle, F.C., Piletz, J. & Musgrave, I.F. (2007) IRAS modulates NGF-induced neurite outgrowth and ERK1/2 activation in PC12 cells. Proceedings of the International Brain Research Organisation World Congress of Neuroscience, Melbourne.
- Dehle, F.C., Piletz, J. & Musgrave, I.F. (2006) Signal transduction pathways underlying the modulation of neurite outgrowth by IRAS. Proceedings of the Australian Health and Medical Research Congress, Melbourne.
- Dehle, F.C., Piletz, J. & Musgrave, I.F. (2005) The candidate imidazoline I₁ receptor, IRAS, enhances neurite outgrowth and ERK1/2 activation in PC12 cells. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Melbourne.
- Dehle, F.C., Piletz, J. & Musgrave, I.F. (2005) Is the candidate imidazoline I₁ receptor, IRAS, a neurotrophin? Proceedings of the Australian Society of Neuroscience, Perth.
- Dehle, F.C., Piletz, J. & Musgrave, I.F. (2004) The candidate imidazoline I₁ receptor, IRAS, stimulates growth cone development in PC-12 cells. Proceedings of the 8th World Conference on Clinical Pharmacology and Therapeutics, Brisbane.

Abbreviations

Alzheimer's disease	AD
Central nervous system	CNS
Diacylglycerol	DAG
Epidermal growth factor	EGF
Extracellular signal-regulated kinase	ERK
G-protein coupled receptor	GPCR
I ₁ Receptor	I ₁ -R
Imidazoline antisera-selected	IRAS
Lysophosphatidic acid	LPA
Lysophospholipid	LP
Mitogen activated protein	MAP
μ opioid receptor	MOR
Nerve growth factor	NGF
Phosphatidylcholine-specific phospholipase C	PC-PLC
Phosphatidylinositol-3-phosphate	PI3P
Phosphoinositide	PI
Protein kinase C	PKC
Protein tyrosine kinase	PTK
Rat embryonic fibroblast	REF
Rostral ventrolateral medulla	RVLM
Sorting Nexin	SNX
Sphingosine-1-phosphate	S1P
Sphingosine kinase	SphK